Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 6, 2014, Pages 1093-1102

  Xu, Hua Xiang ^a,b   Chen, Tao ^a,b   Wang, Wen Quan ^a,b   Wu, Chun Tao ^a,b   Liu, Chen ^a,b   Long, Jiang ^a,b   Xu, Jin ^a,b   Zhang, Ying Jian ^a,b   Chen, Run Hao ^b   Liu, Liang ^a,b   Yu, Xian Jun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Carbohydrate antigen 19 9; Metabolic tumour burden; Metabolic tumour volume; Pancreatic ductal adenocarcinoma; Total lesion glycolysis

Indexed keywords

CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18; CARBOHYDRATE ANTIGEN 199, HUMAN; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE MARKER; FEMALE; GLYCOLYSIS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; TUMOR RECURRENCE; TUMOR VOLUME; VERY ELDERLY; BLOOD; CARCINOMA, PANCREATIC DUCTAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MIDDLE AGED; MULTIMODAL IMAGING; PANCREATIC NEOPLASMS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84900815047     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2688-8     Document Type: Article

References (31)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-20.
2. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74-85.
3. Jamieson NB, Mohamed M, Oien KA, Foulis AK, Dickson EJ, Imrie CW, et al. The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2012;19:3581-90.
4. Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 2013;258:336-46.
5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-6.
6. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004;29:179-87.
7. Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer. 2010;103:1057-65.
8. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez- delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897-902.
9. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003;138:951-6.
10. Heinrich S, Goerres GW, Schafer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235-43.
11. Lee SM, Kim TS, Lee JW, Kim SK, Park SJ, Han SS. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Clin Nucl Med. 2011;36:331-6.
12. Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, et al. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257:364-70.
13. Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38:1191-202.
14. Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, et al. Volume-based assessment by 18F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:50-8. doi: 10.1007/s00259-013-2530-8.
15. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27-38.
16. Liu L, Xu HX, Wang WQ, Wu CT, Chen T, Qin Y, et al. Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene. 2013. doi: 10.1038/onc.2013.223.
17. Hu SL, Yang ZY, Zhou ZR, Yu XJ, Ping B, Zhang YJ. Role of SUVmax obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation. Nucl Med Commun. 2013;34:533-9.
18. Kuruva M, Mittal BR, Abrar ML, Kashyap R, Bhattacharya A. Multivariate analysis of various factors affecting background liver and mediastinal standardized uptake values. Indian J Nucl Med. 2012;27:20-3.
19. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-50S.
20. Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol. 2001;19:53-8.
21. Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res. 2008;14:5236-41.
22. Yoshioka M, Sato T, Furuya T, Shibata S, Andoh H, Asanuma Y, et al. Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. J Gastroenterol. 2004;39:50-5.
23. Groheux D, Hatt M, Hindie E, Giacchetti S, de Cremoux P, Lehmann-Che J, et al. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer. 2013;119:1960-8.
24. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40:290-301.
25. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-45.
26. Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294-301.
27. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-66.
28. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030-3.
29. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784-91.
30. Gorenberg M, Hallett WA, O'Doherty MJ. Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging. 2002;29:1324-7.
31. Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784-8.